

ASX RELEASE

5 February 2016

MMJ Completes Duncan MMPR Pre-License Inspection

MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or the “Company”) is pleased to announce that its wholly-owned subsidiary United Greeneries (“UG”) has completed Health Canada’s (“HC”) Pre-License Inspection of the Company’s Duncan Facility pursuant to Canada’s Federal Marihuana for Medical Purposes Regulations (“MMPR”). Over a three day period from February 1st to 3rd 2016, HC inspectors were onsite at the Duncan Facility verifying information submitted by UG as part of its application to become a Licensed Producer (“LP”) under the MMPR and assessing compliance with the applicable sections of the MMPR prior to license approval. Pre-License Inspection is the final stage prior to Licensing in the application process to become a LP under the MMPR.

MMJ understands that the inspectors are required to submit a report outlining the results of the Pre-License Inspection to HC in Ottawa within two weeks of the inspection. Subsequent to that, it is expected that HC will respond to the Company within two to four weeks.

Ends

For more information please contact

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

For media enquiries

Market Eye
Rob Gundelach, Director
+61 424 930 789
robert.gundelach@marketeye.com.au

About MMJ PhytoTech Limited

MMJ PhytoTech Limited is a vertically integrated medical cannabis (MC) company operating globally. The Company aims to commercialise MC and a growing portfolio of sophisticated MC delivery technologies to the rapidly growing international market for legal medical cannabis. The Company operates under three main subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.

United Greeneries is MMJ’s Canadian-based MC cultivation subsidiary. UG has two facilities with pending MMPR applications, the Duncan Facility on Vancouver Island, BC, and Lucky Lake located in SK. The Company’s flagship MMPR applicant is the Duncan Facility which has received notice from Health Canada of a Pre-License Inspection commencing February 1 2016. The Duncan Facility is a state-of-the-art MC cultivation facility with a capacity of up to 1000 KG of dried MC production per year.

ASX RELEASE

Satipharm is the company's pharmaceutical processing subsidiary with global subsidiaries for regional operation (Switzerland, Australia and Canada). Satipharm is involved with the extraction, refinement & sales of derivative MC products contained in exclusive sophisticated delivery technologies such as special microgel capsules which dramatically increase bioavailability of fat soluble Cannabinoids or a unique new process of creating water soluble solutions from fat soluble cannabinoids.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company conducts R&D for the larger group and performs clinical trials on various quick-to-market delivery technologies etc.

<http://www.mmjphytotech.com.au>

For personal use only